Sensex 27,676.04
-210.17 (-0.75%)
Nifty 8,377.75
-70.35 (-0.83%)
APPS  |  CONTACT US  |  CAREERS  |  LOCATE US  |  DOWNLOADS  |  BLOG
Financial Services | Broking & Distribution | Asset Management | Private Wealth Management | Home Finance | Private Equity | Institutional Equities | Investment Banking | Commodities
Broking & Distribution > Markets > Company Information > News

Aurobindo Pharma Ltd

BSE Code : 524804   |   NSE Symbol : AUROPHARMA   |   ISIN : INE406A01037
OVERVIEW INFORMATION FINANCIALS COMPANY NEWS CORPORATE ACTIONS
 
Aurobindo Pharma receives final approval for Cefixime for Oral Suspension USP  15-Apr-2015 | 12:39
Aurobindo Pharma announced that the Company has received final approvals from the United States Food & Drug Administration (US FDA) to manufacture and market Cefixime for Oral Suspension USP, 100mg/5mL and 200mg/5mL (ANDA 204835). The product is ready for launch. The approved ANDAs are bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Suprax® Oral Suspensio...
Aurobindo Pharma divest from its step-down subsidiary, Aurobindo Pharma (Austral..  10-Apr-2015 | 13:21
Aurobindo Pharma announced that Aurobindo Pharma (APL) has divested its step-down subsidiary, Aurobindo Pharma (Australia) to Eris Pharma Australia. APL will, however, under an agreement continue to manufacture and supply the products to Eris Pharma for Australian and New Zealand market over next few years. This divestment is in line with APL's strategy of focusing on US, EU and Key Emerging Marke...
Aurobindo Pharma receives final approval for Atracurium Besylate Injections  09-Apr-2015 | 12:44
Aurobindo Pharma announced that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Atracurium Besylate Injection, 10mg/mL, 5mL single-dose vials (ANDA 206010) and 10mg/mL, 10mL multi-dose vials(ANDA 206011).The approved ANDAs are bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Atracurium Besyl...
Aurobindo Pharma receives approval for Sildenafil Injection  06-Apr-2015 | 15:19
Aurobindo Pharma announced that the Company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Sildenafil Injection, 10mg/12.5mL (0.8mg/mL). Sildenafil Injection 10mg/12.5mL (0.8mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD), Revatio® (sildenafil) Injection, 10 mg/12.5 mL (0.8 mg/mL), ofPfizer....
Aurobindo Pharma appoints director   25-Mar-2015 | 14:59
Aurobindo Pharma announced that the Board of Directors of the Company vide Circular Resolution dated 25 March 2015 have appointed Dr. Avnit Bimal Singh as an Additional Director (Non-Executive, Independent) of the Company w.e.f. 25 March 2015.Powered by Capital Market - Live News...
Aurobindo Pharma gets tentative approval for Lacosamide Tablets   19-Mar-2015 | 14:18
Aurobindo Pharma announced that US Food & Drug Adminstration has granted tentative approval for Lacosamide Tablets 50mg, 100mg, 150mg and 200 mg. Lacosamide Tablets are the generic equivalent of USB Inc's Vimpat® Tablets and used in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older with a market size of approximately USD 593 million for the twelve months...
Aurobindo Pharma allots equity shares   12-Mar-2015 | 14:16
Aurobindo Pharma announced that the Compensation Committee of the Company on 12 March 2015 has made allotment of 1,86,354 Equity Shares of Re.1/- each under ESOP-2006 Scheme of the Company, Consequent to the allotment, the paid up share capital of the Company has increased from 29,17,95,921 Equity Shares of Re.1/- each to 29,19,82,275 Equity Shares of Re.1/- each.Powered by Capital...
Board of Aurobindo Pharma recommends dividend  06-Feb-2015 | 10:42
Aurobindo Pharma announced that the Board of Directors of the Company at its meeting held on 4 February 2015, inter alia, have recommended the dividend of Rs 2 per equity Share (i.e. 200%) , subject to the approval of the shareholders.Powered by Capital Market - Live News...
Aurobindo Pharma fixes record date for 2nd interim dividend   05-Feb-2015 | 10:04
Aurobindo Pharma has fixed 18 February 2015 as the Record Date for the purpose of payment of Second Interim Dividend 2014-15.The Second Interim Dividend will be paid on or before 25 February 2015.Powered by Capital Market - Live News...
Board of Aurobindo Pharma approves proposal to set up JV with Tergene Biotech   04-Feb-2015 | 21:22
Aurobindo Pharma announced that the Board of Directors of the Company at its meeting held on 04 February 2015, inter alia, has approved the proposal for setting up a Joint Venture (JV) with Tergene Biotech, a vaccine development company based in India. Tergene works on development of the Pneumococcal Conjugate Vaccine (PCV) through use of cutting edge vaccine technology compressing time and cos...
  Company Information :   Company List A-Z  |   Snapshot  |   Volume Chart  |   Investor Returns  |   Score Board  |   Company Peer Comparison  |   Background  |   Board of Directors  |   Quarterly Results  |   Balance Sheet  |   Share Holding Pattern  |   MF Holdings  |   Profit & Loss  |   Key Ratios / Cash Flow  |   Company News  |   Bonus / Split / Rights  |   Dividend / Book Closure  |   Capital Structure  |   Insider Trading History  |   Top Companies By MCAP  |   Top Dividend Yield  
  Equity Market       Derivatives       Mutual Funds       Commodities       Currencies       News       IPO    
Login
Login Open An Account Trade Now
7 day Free trial of our advice
High Speed Multi Asset trading - Orion Lite
Trading Insights
Trading Tool - Trade Guide Signal
Currency Daily Report
Financial Services Products & ServicesBusiness PartnerMarket InfoResearchQuick LinksBusinesses
Stocks   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Mutual Funds   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Commodities   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Disclaimer | Cookie Policy | Additional Disclaimer for U.S. Persons  | Feedback | Locate Us | Do Not Call Form
Motilal Oswal Securities Ltd. (MOSL) Member of NSE, BSE and MCX-SX
Regd Office: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; CIN no.: U65990MH1994PLC079418; Tel No.: 022 3980 4263
Correspondence Office Address: Motilal Oswal Securities Limited, Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West) Mumbai – 400064.; Tel No.: 022 3080 1000

Customer having any query / feedback / clarification may write to query@motilaloswal.com
In case of grievances for Securities Broking write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com, for Commodity Broking to commoditygrievances@motilaloswal.com


Registration Nos: NSE(Cash) INB231041238; NSE(F&O): INF231041238; NSE(CD): INE231041238; BSE(Cash): INB011041257; BSE(F&O) INF011041257; BSE(CD); MCX-SX (Cash) : INB261041231; MCX-SX (F&O): INF261041231; MCX-SX (CD): INE261041231; CDSL: IN-DP-CDSL-09-99; NSDL: IN-DP-NSDL-152-2000; AMFI:ARN 17397. PMS: INP000000670; PMS & Mutual Funds are offered through Motilal Oswal Asset Management Company Ltd(MOAMC) which is group company of MOSL. PMS (Regn No. INP000004409) is offered through Motilal Oswal Wealth Management Ltd. (MOWML) which is a group company of MOSL. Motilal Oswal Commodities Broker Pvt Ltd. (MOCBPL) member of MCX, NCDEX and NCDEX Spot. MCX Member ID 29500, NCDEX-NCDEX-CO-04-00114, NCDEX Spot Exchange Limited 10014. FMC Unique membership code: MCX: MCX/TCM/CORP/0725, NCDEX: NCDEX/TCM/CORP/0033, Commodity Services are offered through MOCBPL which a group company of Motilal Oswal Securities Ltd. Motilal Oswal Securities Ltd is a distributor of Mutual Fund & IPOs. Investment in Securities is subject to market risk.
Motilal Oswal Securities International Pvt Limited CRD-164319 SEC - 08-69093
Copyright © 2015 MOSL. All Rights Reserved. Market Data provided by C-MOTS Infotech (ISO 9001:2008 Certified)

Site best viewed in IE 7.0+, Mozila Firefox 3.0+ and Google Chrome at 1024 x 768 pixels resolution
GET QUOTES    RESEARCH REPORT  
Our research reports can be searched based on companies covered (COM), sectors covered (SEC) or report names (RPT). Type any three characters of your query to see a search list.